vadimezan
Term · Oncology and biomedicine · MLC-T-ONC-017444
A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.
| Identifier | MLC-T-ONC-017444 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | DMXAA |
| Synonyms | Dimethyloxoxanthene Acetic Acid |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017444",
"term": "vadimezan",
"field": "Oncology and biomedicine",
"definition": "A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.",
"abbreviation": "DMXAA",
"synonyms": [
"Dimethyloxoxanthene Acetic Acid"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vadimezan/"
}
Record 17,068 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.